Flu vaccine selection
Executive Summary
Vaccines & Related Biological Products Advisory Committee postpones until mid-March selection of influenza A H3N2 vaccine strain for 2003-2004 flu season pending further analysis of new virus strains. Current vaccine strain, A/Panama/2007/99, has been ineffective at inhibiting recent strains marked by altered amino acid sequence, FDA and CDC reps said during Feb. 20 meeting. FDA committee is expected to hold teleconference March 17 or 18 on strain selection, at which time the panel also could hear data about occurrence of avian influenza virus (A H5N1) in Hong Kong. Committee voted to retain current A H1N1 (New Caledonia/20/99) and B (Hong Kong/330/2001 and 1434/02) strains...
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: